ASCO: Survival Up With Ribociclib in Advanced Breast Cancer
OS longer for premenopausal patients receiving ribociclib in addition to endocrine therapy
ASCO: Combo Regimen Effective in CLL With Coexisting Conditions
Progression-free survival longer with venetoclax-obinutuzumab versus chlorambucil-obinutuzumab
May 2019 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for May 2019. This roundup includes the latest...
ASCO: Low-Dose Chemo Benefits Advanced Gastroesophageal Cancer
Elderly, frail receiving 60 percent of oxaliplatin/capecitabine dose have noninferior PFS, less toxicity
Current Strategies for Measles Vaccination Insufficient
Current policies will not eliminate measles or prevent future resurgence in seven high-income countries
Guidelines Issued for Addressing Heart Disease Risk in HIV
Individuals with HIV have significantly higher rates of CVD, may have underuse of statins, antithrombotics
ASCO: Pembrolizumab Noninferior to Chemo in Advanced Gastric Cancer
For patients with PD-L1 combined positive score of ≥10, pembrolizumab prolongs overall survival
FDA Takes Hard Look at CBD
CBD products have swamped the market due to change in federal law, not because of new medical evidence
Many Buprenorphine Prescribers Not Offering New Appointments
However, for those offering new appointments, wait times were not long to receive buprenorphine
Excess Cause-Specific Mortality Tied to Chronic Proton Pump Inhibitor Use
Excess mortality due to CVD, CKD, upper GI cancer for those with no indication for PPI use
